These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2775467)

  • 21. Differential effects of the dopamine antagonist remoxipride on apomorphine induced behaviour in the rat.
    Ståhle L; Ljungberg T; Rodebjer A; Ogren SO; Ungerstedt U
    Pharmacol Toxicol; 1987 Mar; 60(3):227-32. PubMed ID: 2884654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blockade of apomorphine-induced yawning in rats by the dopamine autoreceptor antagonist (+)-AJ 76.
    Dourish CT; Herbert EN; Iversen SD
    Neuropharmacology; 1989 Dec; 28(12):1423-5. PubMed ID: 2615920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of dihydropyridine compounds in behavioural tests of dopaminergic activity.
    Bourson A; Gower AJ; Mir AK; Moser PC
    Br J Pharmacol; 1989 Dec; 98(4):1312-8. PubMed ID: 2482105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of dopamine autoreceptor agonist properties of apomorphine, (+)-3-PPP and (-)-3-PPP by recording of yawning behaviour in rats.
    Ståhle L; Ungerstedt U
    Eur J Pharmacol; 1984 Feb; 98(2):307-10. PubMed ID: 6714314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antagonism of apomorphine-induced yawning by SCH 23390: evidence against the autoreceptor hypothesis.
    Morelli M; Longoni R; Spina L; Di Chiara G
    Psychopharmacology (Berl); 1986; 89(2):259-60. PubMed ID: 3088647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of age on behavioral responses to dopamine agonists in the rat.
    Ushijima I; Mizuki Y; Soeda K; Kishimoto O; Hara T; Yamada M
    Eur J Pharmacol; 1987 Jun; 138(1):101-6. PubMed ID: 2887433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotic substances and dopamine in the rat brain; behavioral studies reveal distinct dopamine receptor systems.
    Van Ree JM; Elands J; Király I; Wolterink G
    Eur J Pharmacol; 1989 Aug; 166(3):441-52. PubMed ID: 2572429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of pretreatment with luteinizing hormone releasing hormone (LHRH) on behaviors induced by apomorphine in rats.
    Mora S; Diaz-Veliz G
    Pharmacol Biochem Behav; 1988 Oct; 31(2):291-6. PubMed ID: 3072567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Behavioral and cross sensitization after repeated exposure to modafinil and apomorphine in rats.
    Chang ST; Tung CS; Lin YL; Chuang CH; Lee AR; Liu YP
    Chin J Physiol; 2010 Oct; 53(5):318-27. PubMed ID: 21793343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of apomorphine, TL-99 and 3-PPP on yawning in rats.
    Mogilnicka E; Boissard CG; Delini-Stula A
    Neuropharmacology; 1984 Jan; 23(1):19-22. PubMed ID: 6144063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of drinking by naltrexone in the rat: interaction with the dopamine D-1 antagonist SCH 23390 and the D-2 antagonist sulpiride.
    Ukai M; Nakayama S; Kameyama T
    Pharmacol Biochem Behav; 1989 Mar; 32(3):651-5. PubMed ID: 2662222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two distinctive apomorphine-induced phenotypes in the Roman high- and low-avoidance rats.
    Giménez-Llort L; Cañete T; Guitart-Masip M; Fernández-Teruel A; Tobeña A
    Physiol Behav; 2005 Nov; 86(4):458-66. PubMed ID: 16154604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topographical Assessment of Ethological and Dopamine Receptor Agonist-Induced Behavioral Phenotype in Mutants with Congenic DARPP-32 'Knockout'.
    Nally RE; McNamara FN; Clifford JJ; Kinsella A; Tighe O; Croke DT; Fienberg AA; Greengard P; Waddington JL
    Neuropsychopharmacology; 2003 Dec; 28(12):2055-63. PubMed ID: 12865890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Behavioral differentiation of the stimulus properties of a dopaminergic D1 agonist from a D2 agonist.
    Cory-Slechta DA; Widzowski DV; Newland MC
    J Pharmacol Exp Ther; 1989 Sep; 250(3):800-8. PubMed ID: 2789282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogens antagonize apomorphine-induced yawning in rats.
    Serra G; Collu M; Serra A; Gessa GL
    Eur J Pharmacol; 1984 Sep; 104(3-4):383-6. PubMed ID: 6499930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioural manifestations elicited by apomorphine, influence of the route of administration.
    Barros HM; Braz S; Carlini EA
    Pharmacology; 1989; 38(5):335-40. PubMed ID: 2762376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavioral response profiles following drug challenge with dopamine receptor subtype agonists and antagonists in developing rat.
    Sobrian SK; Jones BL; Varghese S; Holson RR
    Neurotoxicol Teratol; 2003; 25(3):311-28. PubMed ID: 12757828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of age on behavioral responses and tissue levels of apomorphine in the rat.
    Campbell A; Baldessarini RJ; Stoll A; Teicher MH; Maynard P
    Neuropharmacology; 1984 Jul; 23(7A):725-30. PubMed ID: 6540844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of single and repeated treatment with antidepressants on apomorphine-induced yawning in the rat: the implication of alpha-1 adrenergic mechanisms in the D-2 receptor function.
    Delini-Stula A; Hunn C
    Psychopharmacology (Berl); 1990; 101(1):62-6. PubMed ID: 1971448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dissociation of autoreceptor activation and behavioral consequences of low-dose apomorphine treatment.
    Lynch MR
    Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(5):689-98. PubMed ID: 1956995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.